Curated News
By: NewsRamp Editorial Staff
September 17, 2026
VERAXA Appoints Raju Willener as CFO to Drive BiTAC Oncology Pipeline
TLDR
- VERAXA named Raju Willener CFO, adding 30 years of capital markets expertise to advance its BiTAC oncology pipeline and gain a strategic edge.
- VERAXA appointed Raju Willener as CFO, effective immediately, to oversee financial strategy as the company advances its BiTAC platform and antibody-drug conjugate pipeline.
- VERAXA's new CFO Raju Willener will help drive novel cancer therapies forward, potentially improving outcomes for patients through BiTAC and T-cell engager technologies.
- VERAXA just appointed Raju Willener as CFO, bringing 30 years of global finance experience to boost its innovative BiTAC cancer therapies.
Impact - Why it Matters
The appointment of a CFO with three decades of capital-markets experience signals VERAXA's readiness to scale its operations and potentially accelerate the development of its BiTAC platform. For investors, this could mean improved financial strategy and access to funding as the company progresses toward clinical milestones. The early promise of BiTAC-ADC and T-cell engager technologies offers hope for more effective cancer treatments, making VERAXA a company to watch in the competitive oncology space.
Summary
VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has appointed Raju Willener as chief financial officer, effective immediately. Willener brings more than 30 years of international experience in investment banking, corporate finance, asset management and capital markets, and he will report directly to CEO and co-founder Christoph Antz, Ph.D. His appointment comes as VERAXA advances its proprietary BiTAC platform and a pipeline centered on antibody-drug conjugates and T-cell engagers.
Prior to joining VERAXA, Willener served as director of corporate development at Exentis Group AG, where he played a key role in strategic initiatives. His deep capital-markets expertise is expected to be instrumental as the company pushes forward with its innovative oncology programs. VERAXA has reported encouraging early data for its BiTAC technologies, including an in-vitro proof of concept for its BiTAC-ADC platform, signaling potential for novel cancer treatments.
The company’s progress and this strategic hire are detailed in a recent announcement, which can be Read More>>. Investors and stakeholders can find additional updates in the company’s newsroom at https://ibn.fm/VRXA. The announcement was distributed through MissionIR, a specialized communications platform that is part of the Dynamic Brand Portfolio @ IBN, which provides wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution and corporate communications solutions.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, VERAXA Appoints Raju Willener as CFO to Drive BiTAC Oncology Pipeline
